The East Asian Pharmaceutical Market Will Reach $121.5bn In 2020 Predicts New Visiongain Report

11 September 2018
Pharma

A new report by visiongain predicts that the East Asian pharmaceutical market will reach $121.5bn in 2020. This forecast and others appear in East Asian Pharmaceutical Market 2016-2026: Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea, published in March 2016. Visiongain is a business information provider based in London, UK.

The East Asian Pharmaceutical Market 2016-2026: Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea report examines the current and future trends in the growing East Asian pharmaceutical market. Among the issues affecting the region is the rapid ageing of the population in each country. An ageing population results in increased demands upon healthcare systems due to higher rates of age-related and chronic diseases. The challenge for pharmaceutical companies is to take advantage of the increased market demand, while negotiating the price restrictions and regulations enforced by national governments. The rewards for companies successfully able to navigate this environment could be significant.

In this report, we examine in detail some of the main national markets in the region, and in each we analyse the market for the major drug types, including generics, originator drugs, OTC drugs and biosimilars. Using our experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national markets and drug types, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future. Qualitative analysis of each country’s market is given, taking into account local government policy, politics and economic conditions. Also included is analysis of a number of leading domestic companies in Japan, Taiwan and Korea.

Also included is analysis of some the leading domestic players in each country in the East Asian pharmaceutical market. Recent financial performance is analysed, along with an analysis of news that may influence the course of the company.

Jack Evans, a pharmaceutical and medical devices industry analyst in visiongain, said: “The East Asian pharmaceutical market will undergo rapid change over the next ten years, driven largely by the rapidly ageing populations of the countries included. Ageing will result in expanded demand for pharmaceuticals, but will also place further pressure on the healthcare budgets of each country. The Japanese government has enacted a range of reforms to reduce the impact of its ageing population, centred on increasing the historically low penetration of generic drugs in the market. The Taiwanese healthcare system faces its own challenges, with issues around drug pricing and sourcing among them. With a new government and renewed focus on healthcare as one of the country’s important industries, there is renewed interest in Taiwan’s pharmaceutical market. Korea has made progress in managing the impacts of its ageing population, and is making progress in encouraging the domestic development of new pharmaceutical products to be sold on the world stage. While each country faces a raft of challenges, growth in the region is predicted to continue across the next decade”
Visiongain’s report provides revenue forecasts to 2026 for the East Asian pharmaceutical market and its leading national markets. The report discusses selected leading domestic companies for each national market. These companies include Takeda, Astellas Pharma, Ostuka Pharmaceutical, Daiichi Sankyo, Eisai Co., Standard Chem and Pharma, Chunghwa Chemical and Pharmaceutical, Yung Shin, TWi Biotechnology, OBI Pharmaceutical, Daewoong Pharmaceutical, Samsung Bioepis and Celltrion.

East Asian Pharmaceutical Market 2016-2026: Prospects for Growth Among Drug Classes in Japan, Taiwan and Korea adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever